Expression of Hormone Receptors and HER-2 in Benign and Malignant Salivary Gland Tumors

被引：28
作者：
Can N.T. [1 ,2 ]
Lingen M.W. [1 ]
Mashek H. [3 ]
McElherne J. [3 ]
Briese R. [3 ]
Fitzpatrick C. [3 ]
van Zante A. [2 ]
Cipriani N.A. [1 ]
机构：
[1] Department of Pathology, The University of Chicago Medicine, 5841 S. Maryland Ave, MC 6101, Chicago, 60637, IL
[2] Department of Pathology, University of California San Francisco, 505 Parnassus Avenue, San Francisco, 94143, CA
[3] Constitutional Cytogenetics and Cytogenomics, Department of Pathology, The University of Chicago Medicine, 5841 S. Maryland Ave, Chicago, 60637, IL
来源：
Head and Neck Pathology | 2018年 / 12卷 / 1期
关键词：
Androgen; Estrogen; FISH; HER-2; Hormone receptors; Progesterone; Salivary duct carcinoma; Salivary gland tumors;
D O I：
10.1007/s12105-017-0833-y
中图分类号：
学科分类号：
摘要：
With the advent of targeted therapies, expression of sex hormone receptors and HER-2 in salivary gland tumors (SGTs) is of clinical interest. Previous reports of estrogen (ER) and progesterone (PR) receptor expression have varied. Androgen receptor (AR) and HER-2 overexpression are frequently reported in salivary duct carcinoma (SDC), but have not been studied systematically in other SGTs. This study examines ER, PR, AR, and HER-2 expression in SGTs. Immunohistochemistry for ER, PR, AR, and HER-2 was performed on 254 SGTs (134 malignant). ER, PR, and AR expression was scored using Allred system. HER-2 expression was scored using Dako HercepTest guidelines. FISH for HER-2 amplification was performed on select cases with HER-2 overexpression (2–3+). No SGT demonstrated strong expression of ER or PR. Combined strong AR and HER-2 expression was seen in 22 carcinomas: 14/25 SDC, 3/16 poorly differentiated, two oncocytic, and one each carcinoma ex pleomorphic adenoma, squamous cell, and intraductal carcinoma. Eighteen additional high grade carcinomas had HER-2 overexpression with absent, weak, or moderate AR expression; eight high grade carcinomas had isolated strong AR expression with 0–1+ HER-2 staining. Of 15 tested cases, six demonstrated HER-2 amplification by FISH, all of which had 3+ immunoreactivity. Neither benign nor malignant SGTs had strong expression of ER or PR. None of the benign SGTs overexpressed AR or HER-2. Coexpression of AR and HER-2 should not define SDC, but immunostaining should be considered in high grade salivary carcinomas, as some show overexpression and may benefit from targeted therapy. © 2017, Springer Science+Business Media, LLC.
引用
收藏
页码：95 / 104
页数：9
相关论文
共 35 条
  • [1] Alotaibi A.M., Alqarni M.A., Alnobi A., Tarakji B., Human epidermal growth factor receptor 2 (HER2/neu) in salivary gland carcinomas: a review of literature, J Clin Diagn Res, 9, 2, pp. ZE04-ZE8, (2015)
  • [2] Limaye S.A., Posner M.R., Krane J.F., Fonfria M., Lorch J.H., Dillon D.A., Et al., Trastuzumab for the treatment of salivary duct carcinoma, Oncologist, 18, 3, pp. 294-300, (2013)
  • [3] Masubuchi T., Tada Y., Maruya S., Osamura Y., Kamata S.E., Miura K., Et al., Clinicopathological significance of androgen receptor, HER2, Ki-67 and EGFR expressions in salivary duct carcinoma, Int J Clin Oncol, 20, 1, pp. 35-44, (2015)
  • [4] Nabili V., Tan J.W., Bhuta S., Sercarz J.A., Head C.S., Salivary duct carcinoma: a clinical and histologic review with implications for trastuzumab therapy, Head Neck, 29, 10, pp. 907-912, (2007)
  • [5] Perissinotti A.J., Lee Pierce M., Pace M.B., El-Naggar A., Kies M.S., Kupferman M., The role of trastuzumab in the management of salivary ductal carcinomas, Anticancer Res, 33, 6, pp. 2587-2591, (2013)
  • [6] Simpson R.H., Salivary duct carcinoma: new developments—morphological variants including pure in situ high grade lesions
  • [7] proposed molecular classification, Head Neck Pathol, 7, pp. S48-S58, (2013)
  • [8] Vidal L., Tsao M.S., Pond G.R., Cohen E.E., Cohen R.B., Chen E.X., Et al., Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib, Head Neck, 31, 8, pp. 1006-1012, (2009)
  • [9] Yamamoto N., Minami S., Fujii M., Clinicopathologic study of salivary duct carcinoma and the efficacy of androgen deprivation therapy, Am J Otolaryngol, 35, 6, pp. 731-735, (2014)
  • [10] Barrera J.E., Shroyer K.R., Said S., Hoernig G., Melrose R., Freedman P.D., Et al., Estrogen and progesterone receptor and p53 gene expression in adenoid cystic cancer, Head Neck Pathol, 2, 1, pp. 13-18, (2008)
1234